|
Monday, November 9, 2009
Embassy Suites, Chesterbrook, Pennsylvania (directions)
|
Immunome
A discovery stage biopharmaceutical company
About
|
Immunome is a discovery stage biopharmaceutical company that has created a proprietary Native Human Monoclonal Antibody (N-huMAB) platform. N-huMAbs are in the exact structures created by nature and possess the natural safety and protective power of the human immune system. The strength of the Immunome technology is its ability to capture the innate curative immune response to infectious diseases and vaccines. Because the Immunome method is intrinsically unbiased, Immunome is able to obtain N-huMAbs not accessible by other antibody cloning methods. Immunome has captured high affinity, potent N-huMAbs in several therapeutic classes – infectious disease, neurological illness, and biodefense. Immunome has focused its internal development efforts on the toxins that induce the devastating results of common infectious diseases.
Opportunity: Overall, infectious diseases remain the third leading cause of death in the United States each year and the second ranking cause of death worldwide. The economic impact of infectious diseases is also great, with an estimated annual cost in excess of $120 billion. Current non-specific chemotherapeutic approaches to the majority of infectious diseases have resulted in the emergence of micro-organisms resistant to multiple therapies (superbugs), thus compounding the clinical problem. The use of “pathogen-specific” antibodies represents a novel therapeutic approach to this ever-expanding medical problem.
Development Program: Immunome’s initial development program will target Clostridium difficile infections. C. difficile is the most serious cause of antibiotic-associated diarrhea and can lead to pseudomembranous colitis, a severe and often fatal infection of the colon. In the past 10 years, the incidence and mortality of C. difficile infection have increased 3X and 18X, respectively. Therapeutics for C. difficile infection represent a billion dollar opportunity in the United States alone.
3 Major Issues
|
- Currently most infections are treated with antibiotics. What are the expected hurdles to the clinical acceptance of antibody therapeutics in the treatment of infections?
- What stage of development of the C. difficile antibody will warrant a Series A investment? What is the next development milestone that would warrant additional investment (Series B)?
- Immunome intends to focus development efforts on capital efficient programs yet the platform generates assets outside our core area. What value does a preclinical stage antibody candidate have to a potential licensee?
Program:
|
6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)
8:00 -Tim Pelura PhD, President & CEO of Immunome will deliver the Company's "Elevator" Pitch to the Group
8:20 - A Panel will address 3 Major Issues for the Company
9:00 - Open discussion: members and guests
<Top of the page>
|
 |
|
 Slides
None available at this time
 Audio
None available at this time
 Video
None available at this time
 Webcast
None available at this time
|
|
Contact Info:
Timothy J. Pelura, Ph.D.
President & CEO
Immunome, Inc.
100 Lancaster Avenue
Wynnewood, PA 190967
Email: tjpelura@gmail.com
|
|
|
